– $60 million Series A capital to finance and build disruptive European biotechnology companies in two cutting-edge fields of research: the microbiome and synthetic biology
– Biotech start-up studio model to select and nurture high quality European innovation with revolutionary potential to maximise opportunities for investors and scientists for the benefit of patients
– eureKARE is guided by influential founder, Alexandre Mouradian, accompanied by a highly skilled team and an international Scientific Advisory Board of renowned experts